U.S. Paper and Forestry Products Stock News

Host Hotels & Resorts targets acquisitions after updated 2026 outlook Host Hotels & Resorts (HST) has put potential acquisitions on the agenda after raising its full year 2026 earnings guidance, giving investors fresh information on both its capital plans and profit expectations. See our latest analysis for Host Hotels & Resorts. Host Hotels & Resorts shares trade at $23.29, with the 1-year total shareholder return of 64.64% and 5-year total shareholder return of 89.91% pointing to strong...

In early August 2026, Vestis workers in Indianapolis represented by Teamsters Local 135 ended a 19-day strike by ratifying a three-year agreement that delivers wage increases, a guaranteed 40-hour work week, and Teamsters health care through the Michigan Conference of Teamsters Health and Welfare Fund. Beyond resolving the immediate work stoppage, the deal highlights a reset in labor relations at a time when Vestis is already emphasizing operational discipline and route efficiency across its...

Rockwell Automation (ROK) drew fresh attention after reporting third quarter fiscal 2026 results that exceeded expectations and updating full year guidance, with management now projecting higher sales and earnings for the year. See our latest analysis for Rockwell Automation. Rockwell Automation's latest guidance upgrade comes after a mixed few months for the share price, with the stock down 8.13% on a 7 day share price return and 6.58% on a 30 day share price return, yet still showing a...

RBC Bearings earnings and guidance draw investor focus RBC Bearings (RBC) is in focus after reporting first quarter results on July 31, 2026, with higher sales and net income compared with a year earlier, along with new guidance for the second quarter of fiscal 2027. See our latest analysis for RBC Bearings. At a latest share price of $567.25, RBC Bearings has a year to date share price return of 23.64%, while its 1 year total shareholder return of 42.50% and 5 year total shareholder return...

In early August 2026, Twist Bioscience completed a US$300 million follow-on common stock offering at US$96 per share while raising its fiscal 2026 revenue guidance to US$456 million–US$457 million and reporting a wider quarterly net loss despite higher sales. At the same time, the company moved to resolve legacy securities litigation through a proposed US$17.05 million class-action settlement process, potentially reducing legal uncertainty for shareholders. With Twist boosting revenue...

With global food costs climbing again, as seen in the latest rise in the FAO Food Price Index, investors are watching how pricing power and leadership quality interact. Founder led companies often live or die by the decisions of a single, deeply invested leader. That makes this a compelling moment to focus on founders who are building legacies. This article highlights three standout stocks from the Founder Led Companies screener. The stocks covered below are just a small sample, and the full...

In July 2026, EMCOR Group reported second-quarter 2026 results showing higher sales of US$5,154.89 million and net income of US$403.69 million, while also raising its full-year 2026 revenue, earnings and operating margin guidance. Alongside these stronger results and upgraded outlook, management reiterated its focus on acquisitions that enhance core capabilities and deepen exposure to key end markets, signalling continued emphasis on scaling its service offering. Next, we’ll examine how...

Earlier this week, Argus cut its rating on Century Communities Inc. (CCS), a U.S. homebuilder focused on single-family attached and detached homes, to SELL without citing new operational developments. The absence of fresh business updates around the downgrade highlights how changes in analyst opinions alone can meaningfully sway market expectations for Century Communities. We’ll now examine how Argus’s SELL downgrade may reshape Century Communities’ investment narrative, particularly around...

Freenome (FRNM) stock is in focus after the company and Abbott received U.S. Food and Drug Administration approval for SimpleScreen CRC, a blood based colorectal cancer screening test for average risk adults. See our latest analysis for Freenome. The FDA approval and upcoming U.S. launch of SimpleScreen CRC comes as Freenome trades at US$11.15, with a 30 day share price return of 3.24% and a year to date share price decline of 14.23%. The 1 year total shareholder return is 5.49%, suggesting...

Fears about weakened US democratic guardrails and politicised security decisions are putting the spotlight on defense and security stocks in a new way. Political instability can unsettle markets, yet it can also redirect government attention and budgets. This article looks at how that tension links to real companies. You will see three stocks from our Defense and Security Sector Stocks screener that appear particularly exposed to the current news cycle. The three stocks covered next are just...

F&G Annuities & Life (FG) has drawn fresh attention after reporting second quarter 2026 results that included a net loss alongside higher revenue, followed by newly declared common and preferred dividends. See our latest analysis for F&G Annuities & Life. The recent earnings loss and fresh dividend declarations have come alongside softer momentum in F&G Annuities & Life's stock, with the share price down 7.89% year to date and the 1 year total shareholder return declining 15.77%. This...

Blackstone Mortgage Trust (BXMT) is back in focus after reporting second quarter 2026 results that showed higher reported sales alongside a net loss, reversing the profit recorded in the same period last year. See our latest analysis for Blackstone Mortgage Trust. The latest earnings release and the recent completion of a multi year repurchase program have come against a weak share price backdrop for Blackstone Mortgage Trust. The share price is down 27.36% year to date and the 1 year total...

Hilton Worldwide Holdings earnings, dividend and buyback in focus Hilton Worldwide Holdings (HLT) has drawn investor attention after reporting higher year over year revenue and net income, raising earnings guidance for 2026, and reaffirming its regular dividend and active share repurchase program. See our latest analysis for Hilton Worldwide Holdings. Hilton Worldwide Holdings' latest earnings, dividend affirmation, and ongoing buybacks come after a softer 30 day share price return, while the...

In the past week, UMH Properties, Inc. reported second-quarter 2026 results showing higher revenue of US$71.64 million and net income of US$9.6 million, and it reaffirmed full-year 2026 diluted net income guidance of US$0.07 to US$0.13 per share attributable to common shareholders. The combination of stronger quarterly earnings and management’s decision to maintain earnings guidance highlights growing confidence in UMH’s ability to support expansion in its manufactured home communities and...

Protagonist Therapeutics (PTGX) has drawn fresh attention after reporting second quarter 2026 results that shifted from a net loss to net income of US$162.85 million, with earnings emerging from continuing operations. See our latest analysis for Protagonist Therapeutics. The sharp move from losses to net income has coincided with strong share price momentum for Protagonist Therapeutics, with a 90 day share price return of 40.94% and a year to date share price return of 67.32%. Over a longer...

AI is starting to reshape who earns what, from data center owners to entry level office workers wondering if their role is next in line for automation. That split creates risk for wages and consumer demand, but it also focuses attention on companies that provide the picks and shovels for AI infrastructure. This article looks at three large stocks exposed to that trend and how the same news could help or hurt their long term appeal. The three stocks in this article are just a starting sample,...

Kemper earnings shock and goodwill impairment set the tone Kemper (KMPR) just posted a second quarter net loss of $464.8 million, driven largely by a $460 million non cash goodwill impairment in its specialty auto segment, along with a shift toward tighter, profitability-focused underwriting. See our latest analysis for Kemper. The latest earnings and goodwill impairment news has coincided with a weaker share price backdrop for Kemper, with the stock at US$28.51 and the year to date share...

Why Axogen Stock Is Back in Focus After Q2 Earnings Axogen (AXGN) is back on investor watchlists after its second quarter 2026 earnings report, which combined higher sales with a net loss, along with raised full year revenue guidance and expectations for continued positive free cash flow. See our latest analysis for Axogen. The strong second quarter update, raised 2026 revenue guidance and expectation for continued positive free cash flow help explain why Axogen's share price return is up...

In the past quarter, Omnicell, Inc. reported second-quarter 2026 revenue of US$312.21 million and net income of US$24.29 million, alongside upgraded guidance calling for third-quarter revenue of US$301 million–US$307 million and full-year 2026 revenue of US$1.23 billion–US$1.25 billion. The sharp improvement in profitability versus a year earlier, with net income rising from US$5.64 million to US$24.29 million, highlights how operating efficiency and business mix are influencing Omnicell’s...

BorgWarner Inc. recently reported past second-quarter 2026 results showing slightly higher sales of US$3,648 million and stronger profitability, alongside raising full-year guidance, extending its share repurchase authorization to US$1.35 billion through 2029, and affirming a quarterly dividend of US$0.17 per share. At the same time, BorgWarner has secured multiple new combustion, hybrid, and electrified propulsion program awards across Europe and China, which may enhance its mix of...

Stride (LRN) drew fresh attention after reporting fourth quarter and full year 2026 results, which showed higher net income and earnings per share, along with updated guidance and a change in chief executive leadership. See our latest analysis for Stride. Stride's recent earnings, leadership change and ongoing share repurchase program have come as the share price has risen 27.7% year to date. However, with the 1 year total shareholder return down 44.8%, longer term investors are still relying...

Rapport Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$56.62 million, up from US$26.73 million a year earlier, and a basic loss per share from continuing operations of US$1.19 versus US$0.75. For the first half of 2026, the company’s net loss widened to US$76.47 million, with basic loss per share from continuing operations rising to US$1.61 from US$1.44, highlighting a faster increase in aggregate losses than in per-share terms. We will now consider how this...

In late July 2026, CCC Intelligent Solutions Holdings reported second-quarter 2026 results showing sales of US$285.93 million and net income of US$20.79 million, alongside stronger six-month profitability compared with the prior year. On the same date, management issued revenue guidance of US$289.5–US$291.5 million for the third quarter and US$1.16 billion for 2026, highlighting confidence in the scale of its insurance-focused SaaS platform after completing a US$399.99 million buyback...

ZoomInfo Technologies recently reported second-quarter 2026 results, including US$310.4 million in sales, a US$643.7 million net loss driven by a US$650.5 million goodwill impairment, and raised its full-year 2026 revenue guidance to US$1.21 billion–US$1.22 billion. A new partnership with DemandScience and fresh AI-powered customer case studies highlight ZoomInfo’s push to embed its data and workflows deeper into clients’ go-to-market systems, even as it faces a shareholder class action over...